Questcor Pharmaceuticals (QCOR) 92.08 $QCOR
SmarTrend Watching for Potential Pullback in Shares of Questcor Pharmaceuticals After 1.80% Gain
Comtex SmarTrend(R) - Fri May 16, 4:18PM CDT
Questcor Pharmaceuticals (NASDAQ:QCOR) traded in a range yesterday that spanned from a low of $88.28 to a high of $90.93. Yesterday, the shares gained 1.8%, which took the trading range above the 3-day high of $88.94 on volume of 1.8 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Today's Stocks Driving Success For The Health Care Sector
at The Street - Fri May 16, 12:03PM CDT
TheStreet highlights 3 stocks pushing the health care sector higher today.
Shares of QCOR Up 30.0% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Thu May 15, 9:11AM CDT
SmarTrend identified an Uptrend for Questcor Pharmaceuticals (NASDAQ:QCOR) on April 1st, 2014 at $67.41. In approximately 1 month, Questcor Pharmaceuticals has returned 30.01% as of today's recent price of $87.64.
Questcor (QCOR) is Overbought: Is A Drop Coming? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu May 15, 8:00AM CDT
Questcor (QCOR) is Overbought: Is A Drop Coming?
Questcor Enters Into Development Collaboration Agreement Covering Novel Receptor-Selective Melanocortin Peptides
PR Newswire - Wed May 14, 8:00AM CDT
Questcor Pharmaceuticals, Inc. (Nasdaq: QCOR) today announced that it has entered into a development collaboration agreement with an undisclosed privately held European company to develop novel melanocortin peptides. The collaboration includes an option to acquire the technology during clinical development. Along with the June 2013 acquisition of Synacthen®, this transaction significantly expands Questcor's portfolio of melanocortin therapeutics and further establishes the company as the leader in this important emerging field of medicine.
Post Earnings Update: Questcor Pharmaceuticals Has Climbed 10.5% Higher in Past 2 Weeks (QCOR)
Comtex SmarTrend(R) - Mon May 12, 11:42AM CDT
When Questcor Pharmaceuticals (NASDAQ:QCOR) reported earnings 14 days ago on April 28th, 2014, analysts, on average, expected the company to report earnings of $1.61 on sales of $240.8 million. Questcor Pharmaceuticals actually reported earnings of $1.51 per share on sales of $227.1 million, missing EPS estimates by $0.10 and missing revenue estimates by $13.6 million. Since the company's report, shares of Questcor Pharmaceuticals have risen from $79.05 to $87.34, representing a gain of 10.5% in the past 14 days.
Mallinckrodt Pharmaceuticals and Questcor Pharmaceuticals Announce Early Termination of HSR Act Waiting Period
Business Wire - Mon May 12, 6:01AM CDT
Mallinckrodt plc (NYSE: MNK), and Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR), today announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended ("HSR"
, in connection with Mallinckrodt's proposed acquisition of Questcor, was terminated by the United States Federal Trade Commission on May 9, 2014.
Webcast Schedules, Clinical Study Results, Stock Price Movements, and Grants - Analyst Notes on Illumina, Questcor, Quest Diagnostics, Raytheon and Lockheed Martin
PR Newswire - Mon May 12, 6:00AM CDT
Today, Analysts Review released its analysts' notes regarding Illumina Inc. (NASDAQ: ILMN), Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR), Quest Diagnostics Inc. (NYSE: DGX), Raytheon Co. (NYSE: RTN) and Lockheed Martin Corporation (NYSE: LMT). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/2321-100free.
Scanning Equities that Reached New highs -- Research on Energy Transfer Equity, Questcor Pharma, Health Net, and Molson Coors Brewing
PR Newswire - Thu May 08, 12:30PM CDT
The markets on Wednesday, May 07, 2014 ended on a mixed note as the Dow Jones Industrial Average finished the day at 16,518.54, up 0.72%, and the NASDAQ Composite closed at 4,067.67, down 0.32%. The S&P 500 finished the session 0.56% higher at 1,878.21. The gains were broad based as eight out of ten sectors ended the session in positive. Investor-Edge looks at some of the equities that hit a new 52-week high during the last session. These include Energy Transfer Equity L.P. (NYSE: ETE), Questcor Pharmaceuticals Inc. (NASDAQ: QCOR), Health Net Inc. (NYSE: HNT) and Molson Coors Brewing Company (NASDAQ: TAP). Free technical research on ETE, QCOR, HNT and TAP can be downloaded upon signing up at:
Valeant Q1 Mixed, But Strong 2014 Guidance Affirmed
at Investor's Business Daily - Thu May 08, 10:19AM CDT
Canadian drugmaker Valeant Pharmaceuticals International (VRX) reported a mixed but mostly in-line Q1 Thursday, as management continued to press its case for a merger with Allergan (AGN). Valeant's stock rose fractionally on the stock market today....
Mallinckrodt plc Reports Fiscal 2014 Second Quarter Financial Results; Increases Full-Year 2014 Guidance
Business Wire - Thu May 08, 5:01AM CDT
--Increases guidance on full-year revenue and full-year adjusted diluted earnings per share reflecting strength of base business and acquisition of Cadence
After Yesterday's Rally of 2.53% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Wed May 07, 5:17PM CDT
Questcor Pharmaceuticals (NASDAQ:QCOR) traded in a range yesterday that spanned from a low of $83.51 to a high of $86.51. Yesterday, the shares gained 2.5%, which took the trading range above the 3-day high of $85.00 on volume of 2.2 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Uptrend Call Working As Questcor Pharmaceuticals Stock Rises 28.1% (QCOR)
Comtex SmarTrend(R) - Wed May 07, 4:46PM CDT
SmarTrend identified an Uptrend for Questcor Pharmaceuticals (NASDAQ:QCOR) on April 1st, 2014 at $67.41. In approximately 1 month, Questcor Pharmaceuticals has returned 28.13% as of today's recent price of $86.37.
Akorn Q1 EPS Beats, Raises Full-Year Profit Outlook
at Investor's Business Daily - Tue May 06, 11:11AM CDT
Specialty drugmaker Akorn (AKRX) on Tuesday reported first-quarter EPS above views, but revenue was light. The company also raised its full-year profit outlook. Lake Forest, Ill.-based Akorn said that it earned 16 cents per share in the three months...
Clinical Trial Results Indicate Acthar May Significantly Reduce Disease Activity in Patients with Systemic Lupus Erythematosus
PR Newswire - Mon May 05, 8:00AM CDT
Questcor Pharmaceuticals, Inc. (Nasdaq: QCOR) today announced that results from the first modern clinical study examining the use of H.P. Acthar® Gel (repository corticotropin injection) in systemic lupus erythematosus (SLE) has been published in the journal LUPUS. This independent investigator-initiated ten patient study was conducted at Fiechtner Research, a rheumatology research center, and evaluated the efficacy of Acthar in reducing SLE disease activity among patients who presented with moderately to severely active disease despite receiving traditional SLE maintenance treatments. Acthar is approved by the Food and Drug Administration (FDA) for 19 indications, including for use during an exacerbation or as maintenance therapy in selected cases of systemic lupus erythematosus.
Questcor CEO's Daughter Granted Huge Pay Raise
at The Street - Fri May 02, 11:20AM CDT
Her salary jumps to more than $1 million in 2013 from $300,000 in 2012, according to Questcor disclosure.
Awards, Stock Price Updates, Quarterly Earnings Releases, and Clinical Study Results - Analyst Notes on Aetna, Regeneron, Questcor, Medtronic and Lilly
PR Newswire - Thu May 01, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Aetna Inc. (NYSE: AET), Regeneron Pharmaceuticals Inc. (NASDAQ: REGN), Questcor Pharmaceuticals Inc. (NASDAQ: QCOR), Medtronic Inc. (NYSE: MDT) and Eli Lilly & Co. (NYSE: LLY). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/1903-100free.
Questcor Pharmaceuticals Up 20.4% Since SmarTrend Uptrend Call (QCOR)
Comtex SmarTrend(R) - Wed Apr 30, 11:05AM CDT
SmarTrend identified an Uptrend for Questcor Pharmaceuticals (NASDAQ:QCOR) on April 1st, 2014 at $67.41. In approximately 4 weeks, Questcor Pharmaceuticals has returned 20.36% as of today's recent price of $81.14.
INVESTOR ALERT - Questcor Pharmaceuticals, Inc.: The Law Offices of Vincent Wong Investigates the Sale of Questcor Pharmaceuticals, Inc. to Mallinckrodt
Business Wire - Wed Apr 30, 10:55AM CDT
The Law Offices of Vincent Wong are investigating potential claims against the Board of Directors of Questcor Pharmaceuticals Inc. (NasdaqGS: QCOR) ("Questcor" in connection with the sale of the Company to Mallinckrodt.
Small-Cap Growth Stocks: On a Roll With Room to Run
Selena Maranjian, The Motley Fool - Motley Fool - Tue Apr 29, 4:17PM CDT
Exchange-traded funds offer a convenient way to invest in sectors or niches that interest you. If you'd like to add some small-cap growth stocks to your portfolio but don't have the time or expertise to hand-pick a few, the Vanguard Russell 2000...
SmarTrend Watching for Potential Pullback in Shares of Questcor Pharmaceuticals After 1.80% Gain
Comtex SmarTrend(R) - Fri May 16, 4:18PM CDT
Questcor Pharmaceuticals (NASDAQ:QCOR) traded in a range yesterday that spanned from a low of $88.28 to a high of $90.93. Yesterday, the shares gained 1.8%, which took the trading range above the 3-day high of $88.94 on volume of 1.8 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Today's Stocks Driving Success For The Health Care Sector
at The Street - Fri May 16, 12:03PM CDT
TheStreet highlights 3 stocks pushing the health care sector higher today.
Shares of QCOR Up 30.0% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Thu May 15, 9:11AM CDT
SmarTrend identified an Uptrend for Questcor Pharmaceuticals (NASDAQ:QCOR) on April 1st, 2014 at $67.41. In approximately 1 month, Questcor Pharmaceuticals has returned 30.01% as of today's recent price of $87.64.
Questcor (QCOR) is Overbought: Is A Drop Coming? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu May 15, 8:00AM CDT
Questcor (QCOR) is Overbought: Is A Drop Coming?
Questcor Enters Into Development Collaboration Agreement Covering Novel Receptor-Selective Melanocortin Peptides
PR Newswire - Wed May 14, 8:00AM CDT
Questcor Pharmaceuticals, Inc. (Nasdaq: QCOR) today announced that it has entered into a development collaboration agreement with an undisclosed privately held European company to develop novel melanocortin peptides. The collaboration includes an option to acquire the technology during clinical development. Along with the June 2013 acquisition of Synacthen®, this transaction significantly expands Questcor's portfolio of melanocortin therapeutics and further establishes the company as the leader in this important emerging field of medicine.
Post Earnings Update: Questcor Pharmaceuticals Has Climbed 10.5% Higher in Past 2 Weeks (QCOR)
Comtex SmarTrend(R) - Mon May 12, 11:42AM CDT
When Questcor Pharmaceuticals (NASDAQ:QCOR) reported earnings 14 days ago on April 28th, 2014, analysts, on average, expected the company to report earnings of $1.61 on sales of $240.8 million. Questcor Pharmaceuticals actually reported earnings of $1.51 per share on sales of $227.1 million, missing EPS estimates by $0.10 and missing revenue estimates by $13.6 million. Since the company's report, shares of Questcor Pharmaceuticals have risen from $79.05 to $87.34, representing a gain of 10.5% in the past 14 days.
Mallinckrodt Pharmaceuticals and Questcor Pharmaceuticals Announce Early Termination of HSR Act Waiting Period
Business Wire - Mon May 12, 6:01AM CDT
Mallinckrodt plc (NYSE: MNK), and Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR), today announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended ("HSR"
, in connection with Mallinckrodt's proposed acquisition of Questcor, was terminated by the United States Federal Trade Commission on May 9, 2014. Webcast Schedules, Clinical Study Results, Stock Price Movements, and Grants - Analyst Notes on Illumina, Questcor, Quest Diagnostics, Raytheon and Lockheed Martin
PR Newswire - Mon May 12, 6:00AM CDT
Today, Analysts Review released its analysts' notes regarding Illumina Inc. (NASDAQ: ILMN), Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR), Quest Diagnostics Inc. (NYSE: DGX), Raytheon Co. (NYSE: RTN) and Lockheed Martin Corporation (NYSE: LMT). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/2321-100free.
Scanning Equities that Reached New highs -- Research on Energy Transfer Equity, Questcor Pharma, Health Net, and Molson Coors Brewing
PR Newswire - Thu May 08, 12:30PM CDT
The markets on Wednesday, May 07, 2014 ended on a mixed note as the Dow Jones Industrial Average finished the day at 16,518.54, up 0.72%, and the NASDAQ Composite closed at 4,067.67, down 0.32%. The S&P 500 finished the session 0.56% higher at 1,878.21. The gains were broad based as eight out of ten sectors ended the session in positive. Investor-Edge looks at some of the equities that hit a new 52-week high during the last session. These include Energy Transfer Equity L.P. (NYSE: ETE), Questcor Pharmaceuticals Inc. (NASDAQ: QCOR), Health Net Inc. (NYSE: HNT) and Molson Coors Brewing Company (NASDAQ: TAP). Free technical research on ETE, QCOR, HNT and TAP can be downloaded upon signing up at:
Valeant Q1 Mixed, But Strong 2014 Guidance Affirmed
at Investor's Business Daily - Thu May 08, 10:19AM CDT
Canadian drugmaker Valeant Pharmaceuticals International (VRX) reported a mixed but mostly in-line Q1 Thursday, as management continued to press its case for a merger with Allergan (AGN). Valeant's stock rose fractionally on the stock market today....
Mallinckrodt plc Reports Fiscal 2014 Second Quarter Financial Results; Increases Full-Year 2014 Guidance
Business Wire - Thu May 08, 5:01AM CDT
--Increases guidance on full-year revenue and full-year adjusted diluted earnings per share reflecting strength of base business and acquisition of Cadence
After Yesterday's Rally of 2.53% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Wed May 07, 5:17PM CDT
Questcor Pharmaceuticals (NASDAQ:QCOR) traded in a range yesterday that spanned from a low of $83.51 to a high of $86.51. Yesterday, the shares gained 2.5%, which took the trading range above the 3-day high of $85.00 on volume of 2.2 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Uptrend Call Working As Questcor Pharmaceuticals Stock Rises 28.1% (QCOR)
Comtex SmarTrend(R) - Wed May 07, 4:46PM CDT
SmarTrend identified an Uptrend for Questcor Pharmaceuticals (NASDAQ:QCOR) on April 1st, 2014 at $67.41. In approximately 1 month, Questcor Pharmaceuticals has returned 28.13% as of today's recent price of $86.37.
Akorn Q1 EPS Beats, Raises Full-Year Profit Outlook
at Investor's Business Daily - Tue May 06, 11:11AM CDT
Specialty drugmaker Akorn (AKRX) on Tuesday reported first-quarter EPS above views, but revenue was light. The company also raised its full-year profit outlook. Lake Forest, Ill.-based Akorn said that it earned 16 cents per share in the three months...
Clinical Trial Results Indicate Acthar May Significantly Reduce Disease Activity in Patients with Systemic Lupus Erythematosus
PR Newswire - Mon May 05, 8:00AM CDT
Questcor Pharmaceuticals, Inc. (Nasdaq: QCOR) today announced that results from the first modern clinical study examining the use of H.P. Acthar® Gel (repository corticotropin injection) in systemic lupus erythematosus (SLE) has been published in the journal LUPUS. This independent investigator-initiated ten patient study was conducted at Fiechtner Research, a rheumatology research center, and evaluated the efficacy of Acthar in reducing SLE disease activity among patients who presented with moderately to severely active disease despite receiving traditional SLE maintenance treatments. Acthar is approved by the Food and Drug Administration (FDA) for 19 indications, including for use during an exacerbation or as maintenance therapy in selected cases of systemic lupus erythematosus.
Questcor CEO's Daughter Granted Huge Pay Raise
at The Street - Fri May 02, 11:20AM CDT
Her salary jumps to more than $1 million in 2013 from $300,000 in 2012, according to Questcor disclosure.
Awards, Stock Price Updates, Quarterly Earnings Releases, and Clinical Study Results - Analyst Notes on Aetna, Regeneron, Questcor, Medtronic and Lilly
PR Newswire - Thu May 01, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Aetna Inc. (NYSE: AET), Regeneron Pharmaceuticals Inc. (NASDAQ: REGN), Questcor Pharmaceuticals Inc. (NASDAQ: QCOR), Medtronic Inc. (NYSE: MDT) and Eli Lilly & Co. (NYSE: LLY). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/1903-100free.
Questcor Pharmaceuticals Up 20.4% Since SmarTrend Uptrend Call (QCOR)
Comtex SmarTrend(R) - Wed Apr 30, 11:05AM CDT
SmarTrend identified an Uptrend for Questcor Pharmaceuticals (NASDAQ:QCOR) on April 1st, 2014 at $67.41. In approximately 4 weeks, Questcor Pharmaceuticals has returned 20.36% as of today's recent price of $81.14.
INVESTOR ALERT - Questcor Pharmaceuticals, Inc.: The Law Offices of Vincent Wong Investigates the Sale of Questcor Pharmaceuticals, Inc. to Mallinckrodt
Business Wire - Wed Apr 30, 10:55AM CDT
The Law Offices of Vincent Wong are investigating potential claims against the Board of Directors of Questcor Pharmaceuticals Inc. (NasdaqGS: QCOR) ("Questcor"
in connection with the sale of the Company to Mallinckrodt. Small-Cap Growth Stocks: On a Roll With Room to Run
Selena Maranjian, The Motley Fool - Motley Fool - Tue Apr 29, 4:17PM CDT
Exchange-traded funds offer a convenient way to invest in sectors or niches that interest you. If you'd like to add some small-cap growth stocks to your portfolio but don't have the time or expertise to hand-pick a few, the Vanguard Russell 2000...
